{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:34:21Z","timestamp":1791646461344,"version":"4.3.4"},"reference-count":100,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:p>Nonalcoholic fatty liver disease (NAFLD), representing a clinical spectrum ranging from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), is rapidly evolving into a global pandemic. Patients with NAFLD are burdened with high rates of metabolic syndrome\u2010related comorbidities resulting in polypharmacy. Therefore, it is crucial to gain a better understanding of NAFLD\u2010mediated changes in drug disposition and efficacy\/toxicity. Despite extensive clinical pharmacokinetic data in cirrhosis, current knowledge concerning pharmacokinetic alterations in NAFLD, particularly at different stages of disease progression, is relatively limited. <jats:italic>In vitro<\/jats:italic>\u2010to\u2010<jats:italic>in vivo<\/jats:italic> extrapolation coupled with physiologically based pharmacokinetic and pharmacodynamic (IVIVE\u2010PBPK\/PD) modeling offers a promising approach for optimizing pharmacologic predictions while refining and reducing clinical studies in this population. Use of IVIVE\u2010PBPK to predict intra\u2010organ drug concentrations at pharmacologically relevant sites of action is particularly advantageous when it can be linked to pharmacodynamic effects. Quantitative systems pharmacology\/toxicology (QSP\/QST) modeling can be used to translate pharmacokinetic and pharmacodynamic data from PBPK\/PD models into clinically relevant predictions of drug response and toxicity. In this review, a detailed summary of NAFLD\u2010mediated alterations in human physiology relevant to drug absorption, distribution, metabolism, and excretion (ADME) is provided. The application of literature\u2010derived physiologic parameters and ADME\u2010associated protein abundance data to inform virtual NAFLD population development and facilitate PBPK\/PD, QSP, and QST predictions is discussed along with current limitations of these methodologies and knowledge gaps. The proposed methodologic framework offers great potential for meaningful prediction of pharmacological outcomes in patients with NAFLD and can inform both drug development and clinical practice for this population.<\/jats:p>","DOI":"10.1002\/cpt.2614","type":"journal-article","created":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T09:34:19Z","timestamp":1650101659000},"page":"275-297","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH)"],"prefix":"10.1111","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7476-9248","authenticated-orcid":false,"given":"William A.","family":"Murphy","sequence":"first","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics UNC Eshelman School of Pharmacy University of North Carolina at Chapel Hill  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6781-2113","authenticated-orcid":false,"given":"Jeffry","family":"Adiwidjaja","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics UNC Eshelman School of Pharmacy University of North Carolina at Chapel Hill  Chapel Hill North Carolina USA"},{"name":"Simulations Plus, Inc.  Lancaster California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6960-7757","authenticated-orcid":false,"given":"Noora","family":"Sj\u00f6stedt","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Biosciences Faculty of Pharmacy University of Helsinki  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyunghee","family":"Yang","sequence":"additional","affiliation":[{"name":"DILIsym Services Division Simulations Plus Inc.  Research Triangle Park North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6926-8844","authenticated-orcid":false,"given":"James J.","family":"Beaudoin","sequence":"additional","affiliation":[{"name":"DILIsym Services Division Simulations Plus Inc.  Research Triangle Park North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Spires","sequence":"additional","affiliation":[{"name":"Simulations Plus, Inc.  Lancaster California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott Q.","family":"Siler","sequence":"additional","affiliation":[{"name":"DILIsym Services Division Simulations Plus Inc.  Research Triangle Park North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8809-1960","authenticated-orcid":false,"given":"Sibylle","family":"Neuhoff","sequence":"additional","affiliation":[{"name":"Certara UK Ltd. (Simcyp Division)  Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1945-4929","authenticated-orcid":false,"given":"Kim L.R.","family":"Brouwer","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics UNC Eshelman School of Pharmacy University of North Carolina at Chapel Hill  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.07.060"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2298"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006761"},{"key":"e_1_2_12_6_1","first-page":"290","article-title":"Metabolism of drugs in subjects with Laennec\u2019s cirrhosis","volume":"1","author":"Brodie B.B.","year":"1959","journal-title":"Med. Exp. Int. J. Exp. Med."},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20701"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16489"},{"key":"e_1_2_12_9_1","unstructured":"United States Food and Drug Administration.Guidance for industry: Pharmacokinetics in patients with impaired hepatic function: Study design data analysis and impact on dosing and labeling<https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/pharmacokinetics\u2010patients\u2010impaired\u2010hepatic\u2010function\u2010study\u2010design\u2010data\u2010analysis\u2010and\u2010impact\u2010dosing\u2010and> (2003)."},{"key":"e_1_2_12_10_1","unstructured":"European Medicines Agency.Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function<https:\/\/www.ema.europa.eu\/en\/evaluation\u2010pharmacokinetics\u2010medicinal\u2010products\u2010patients\u2010impaired\u2010hepatic\u2010function> (2005)."},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1717"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13091334"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2017.04.053"},{"key":"e_1_2_12_14_1","unstructured":"United States Food and Drug Administration.Nonalcoholic steatohepatitis with compensated cirrhosis: developing drugs for treatment<https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/nonalcoholic\u2010steatohepatitis\u2010compensated\u2010cirrhosis\u2010developing\u2010drugs\u2010treatment\u2010guidance\u2010industry> (2019)."},{"key":"e_1_2_12_15_1","unstructured":"United States Food and Drug Administration.Noncirrhotic nonalcoholic steatohepatitis with liver fibrosis: developing drugs for treatment<https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/noncirrhotic\u2010nonalcoholic\u2010steatohepatitis\u2010liver\u2010fibrosis\u2010developing\u2010drugs\u2010treatment> (2018)."},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddtec.2021.06.002"},{"issue":"1","key":"e_1_2_12_17_1","first-page":"S160","article-title":"Application of PBPK modeling and simulation for regulatory decision making and its impact on US prescribing information: an update on the 2018\u20132019 submissions to the US FDA\u2019s office of clinical pharmacology","volume":"60","author":"Zhang X.","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1699"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2037"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2015.12.012"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26717"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28709"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-015-3776-8"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014279"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.01.035"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-012-0581-4"},{"key":"e_1_2_12_27_1","first-page":"12","article-title":"Serum levels of acute phase proteins in patients with nonalcoholic steatohepatitis","volume":"14","author":"Koruk M.","year":"2003","journal-title":"Turk. J. Gastroenterol."},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.3402\/ljm.v5i0.5071"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000015"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2006.04266.x"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.8b00159"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.120.000152"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05050610"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105280"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2014.06.015"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13158"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.2165\/11594420-000000000-00000"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1519"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2014.09.004"},{"key":"e_1_2_12_40_1","volume-title":"Effect of non\u2010alcoholic fatty liver disease (NAFLD) on hepatic drug metabolism enzymes in human","author":"Jamwal R.","year":"2018"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2020.10.027"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharep.2019.04.001"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.1c00462"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.041012"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.211284"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13362"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-015-1148-y"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.02.021"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.121.000484"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.116.074732"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.062703"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.997"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.66"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2018.06.013"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13785"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12885"},{"key":"e_1_2_12_57_1","article-title":"Human renal xenobiotic transporter expression is altered in progression of non\u2010alcoholic fatty liver disease as revealed by quantitative targeted proteomics","volume":"109","author":"Jilek J.L.","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2018.1473376"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.115.065979"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.117.077644"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50095"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hepres.2005.10.001"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2011.06760.x"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14111"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2014.08.013"},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0251665"},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-5387"},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2011.573017"},{"key":"e_1_2_12_69_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.019604"},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.117.079624"},{"key":"e_1_2_12_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13962"},{"key":"e_1_2_12_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.701"},{"key":"e_1_2_12_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1537"},{"key":"e_1_2_12_74_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.058446"},{"key":"e_1_2_12_75_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.116.071183"},{"key":"e_1_2_12_76_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.01061"},{"key":"e_1_2_12_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-9861(02)00558-1"},{"key":"e_1_2_12_78_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0407872102"},{"key":"e_1_2_12_79_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfaa019"},{"key":"e_1_2_12_80_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12463"},{"key":"e_1_2_12_81_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.121.000413"},{"key":"e_1_2_12_82_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.120.000291"},{"key":"e_1_2_12_83_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10010036"},{"key":"e_1_2_12_84_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2017.1314461"},{"key":"e_1_2_12_85_1","doi-asserted-by":"publisher","DOI":"10.1002\/1873\u20103468.14318"},{"key":"e_1_2_12_86_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.11.049"},{"key":"e_1_2_12_87_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27395"},{"key":"e_1_2_12_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2010.07.027"},{"key":"e_1_2_12_89_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000531"},{"key":"e_1_2_12_90_1","first-page":"175","article-title":"Comparison of haematological parameters in patients with non\u2010alcoholic fatty liver disease and alcoholic liver disease","volume":"52","author":"Das S.K.","year":"2011","journal-title":"Singapore Med. J."},{"key":"e_1_2_12_91_1","doi-asserted-by":"publisher","DOI":"10.3233\/CH-2011-1509"},{"key":"e_1_2_12_92_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000031"},{"key":"e_1_2_12_93_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184444"},{"key":"e_1_2_12_94_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-008-0063-6"},{"key":"e_1_2_12_95_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17081218"},{"key":"e_1_2_12_96_1","doi-asserted-by":"publisher","DOI":"10.1002\/lt.500050516"},{"key":"e_1_2_12_97_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.109.027466"},{"key":"e_1_2_12_98_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18020434"},{"key":"e_1_2_12_99_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.048439"},{"key":"e_1_2_12_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1665-2681(19)31170-6"},{"key":"e_1_2_12_101_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00310.2017"}],"updated-by":[{"DOI":"10.1002\/cpt.2876","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000}}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.2614","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.2614","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.2614","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:31:27Z","timestamp":1699363887000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.2614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":100,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1002\/cpt.2614"],"URL":"https:\/\/doi.org\/10.1002\/cpt.2614","archive":["Portico"],"relation":{"correction":[{"id-type":"doi","id":"10.1002\/cpt.2876","asserted-by":"object"}]},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,2]]},"assertion":[{"value":"2021-12-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}